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Primary Aldosteronism at Henry Ford Hospital in the 1980s
Max Wisgerhof, MD*

Patients

This report describes the experience with the diagnosis and treatment of primary aldosteronism at
Henry Ford Hospital since 1980. Of the 28 patients who received the diagnosis. 13 had unilateral
primary aldosteronism and 15 had idiopathic hyperaldosteronism. Individual cases are used to
demonstrate clinical points. The clue to the presence of primary aldosteronism in a hypertensive
patient is hypokalemia. The diagnosis is established by showing 1) high plasma aldosterone after
intravenous saline or high urinary aldosterone after treatment with sodium chloride orally, and 2) low
stimulated plasma renin activity. Treatment with potassium supplement should be given during the
testing. Unilateral primary aldosteronism can be identified and localized by adrenal cortical
scintigraphy using 131-iodine iodomethyl 19-norcholesterol (NP-59) during dexamethasone treatment
to decrease Cortisol synthesis. Unilateral adrenalectomy will cure the hypokalemia and relieve (60%)
or improve (90%) the hypertension in unilateral primary aldosteronism. Idiopathic hyperaldosteronism is treated medically, with spironolactone or amiloride and calcium-channel blocking drugs. (Henry FordHosp MedJ 1987:35:226-33)

P

rimary aldosteronism is the excessive secretion of the hormone aldosterone (1-3), from one or both adrenal glands,
without a stimulus detected for the adrenal hyperfunction. The
excess of the hormone leads to excesses of its effects: kaliuresis,
sodium retention, and an increase in blood pressure. Primary aldosteronism is a new syndrome, relative to most other disorders
of hormone excess, and is infrequent in occurrence. One form,
the unilateral, adenomatous one (4), is curable. The bilateral,
idiopathic hyperaldosteronism syndrome (5,6) has yet to be explained, and an aldosterone-stimulating hormone (7) has been
suggested as its cause.
A total of 28 patients, the subjects of this report, have received
the diagnosis of primary aldosteronism at Henry Ford Hospital
since 1980. Thirteen patients had unilateral primary aldosteronism, and 15 patients had idiopathic hyperaldosteronism. Some
of their characteristics are noted in Table 1. The proportion of
males with idiopathic hyperaldosteronism is greater than those
with unilateral aldosterorusm. Individual cases will be used in
this discussion to demonstrate clinical points about the diagnosis and treatment of primary aldosteronism at Henry Ford
Hospital inthe 1980s.

Diagnosis
Clues to the diagnosis
Symptoms are particularly useful during the evaluation of a
patient i f they are reliable, specific clues to the presence of a disease. Patients with primary aldosteronism will not necessarily
have symptoms which suggest the diagnosis:
Case 1—A 44-year-old woman presented with paroxysms of weakness, headache, chest pain, pallor, and hypertension. The spells began
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two years before presentation and were increasing in frequency and
severity. The symptoms suggested pheochromocytoma, but her plasma concentrations of norepinephrine and epinephrine and urinary excretion of catecholamine metabolites were normal. Hypokalemia was
noted, and evaluation disclosed thefindingsof primary aldosteronism
due to a right adrenal aldosterone-producing adenoma (Fig 1). Adrenalectomy relieved the symptoms, cured the hypokalemia, and
markedly improved the hypertension.
Case 2—A 55-year-old man presented with headaches of a few
months duration, with blurred margins of the optic disks, a flameshapwd hemorrhage and a hard exudate in his retina, and a blood pressure of 204/104 mm Hg. Hypokalemia was present, and pursuit ofan
explanation for it led to the demonstration of the presence of bilateral,
idiopathic hyperaldosteronism. Treatment with amiloride and nifedipine relieved the symptoms and controlled his blood pressure and
serum potassium.
The clue to the presence of primary aldosteronism in a hypertensive patient is hypokalemia (8), rather than specific symptoms or signs. Hypokalemia can cause muscle symptoms which
can be severe:
Case 3—A 32-year-old woman presented with acute pain and swelling in her left calf and progressive muscle weakness. She was
anticoagulated for deep vein thrombophlebitis, but venography was
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Table 1
Characteristics of the 28 Patients with Primary
Aldosteronism at Henry Ford Hospital in the 1980s

patients
Female
Male
Black
White
Age at diagnosis (years)
Median
Range
Mean blood pressure
(mm Hg)
Median
Range
Serum potassium
(mEq/L)
Median
Range
Left adrenal affected
Right adrenal affected
Single adenoma*
Multiple adenomas or
nodules

Unilateral
Primary Aldosteronism
(N = 13)
9
4
8
5

Idiopathic
Hyperaldosteronism
(N = 15)
3
12
7
8

41
31-62

56
27-75

127
109-173

128
110-160

3.1
2.8-3.8
8
5
10

3.4
2.8-3.8

*One patient has not been ueated surgically.

negative. She did have rhabdomyolysis and was hypokalemic. Her
evaluation detected a right adrenal aldosteronoma, and adrenalectomy
corrected the hypokalemia and its manifestations and improved the
hypertension.
Surgically-curable primary aldosteronism can be set aside
from further diagnostic consideration in a hypertensive patient
when the seram potassium is greater than 4.0 mEq/L, ifthe patient has not been treated with potassium or potassium-retaining
drags (9).
Establishing the diagnosis
The diagnosis of primary aldosteronism is established
by clearly showing the presence of both inappropriately high
aldosterone secretion and inappropriately low plasma renin
activity. This data can be obtained from standard testing
procedures:
Case 4—A 62-year-old woman presented with severe hypertension
and hypokalemia. Compensated congestive heart failure and cerebral
vascular disease were present. After the intravenous infusion of two
liters of normal saline in four hours, her plasma aldosterone was 28
ng/dL. The removal of a left adrenal aldosterone-producing adenoma
returned her serum potassium to normal and markedly improved her
blood pressure.
The infusion of saline to detect aldosteronism (10) is less hazardous to the hypertensive patient than is giving the parient a
large amount of sodium orally for three days because a severe
hypertensive response to the sodium is more readily controlled
during the close monitoring of the saline infusion. A severe hypertensive response is more likely if the patient does not have
primary aldosteronism and has essential hypertension, particularly in the sodium-sensitive subset. A plasma aldosterone concentration of greater than 10 ng/dL after the saline infusion is
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Fig 1—The aldosterone-producing
adrenal adenoma from
case I had the characteristic,
golden-yellow
color of an
aldosteronoma.
diagnostic of aldosteronism. A normal concentration is less than
8 ng/dL. The protocol and results for this series of patients are
shown in Table 2(A).
Case 5—A 54-year-old man had hypertension, unprovoked hypokalemia, and inappropriate kaliuresis. His plasma aldosterone concentration after two liters of intravenous saline was 4 ng/dL, a normal
result. His serum potassium was 3.6 mEq/L. His urinary aldosterone
was determined during the third 24 hours of treatment with sodium (3 g
of sodium chloride threetimesdaily with meals to prevent gastric irritation), and it was high, 37 iJt.g/24 hr. An aldosterone-producing adrenal
adenoma was removed, and his serum potassium and blood pressure
retumed to nonnal.

Measuring the excretion of aldosterone during the third 24 hours
offi-eatmentwitii 150 mEq of sodium orally per 24 hours is a standard test to detect aldosteronism (11). A normal result is less tiian 8
pg/24 hr The protocol and results for this series of patients is
shown in Table 2(B). Potassium depletion can impair aldosterone
secretion in aldosteronism, and thus lower the urinary excretion and
plasma concentration (12). Once unprovoked hypokalemia and inappropriate kaliuresis have been demonstrated, potassium supplement treatment should be given to achieve a normal seram
potassium concentration, i f possible, during assessment of aldosterone secretion.

Case 6—A 36-year-old woman presented with hypokalemia and hypertension. Her aldosterone excretion was 12 |jLg/24 hr during sodium
treatment. Her plasma aldosterone concentration was 16 ng/dL after
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intravenous saline. Subsequentiy, a diagnosis of bilateral, idiopathic
hyperaldosteronism was obtained.
Aldosteronism is usually less severe in idiopathic hyperaldosteronism than in aldosterone-producing adenoma, and the
results from both the saline infusion test and the assessment of
aldosterone excretion can be useful in establishing the diagnosis
of idiopathic hyperaldosteronism.
Low stimulated plasma renin activity is a requirement for the
diagnosis of primary aldosteronism and can be demonstrated
utilizing protocols which measure the response of plasma renin
activity to acute sodium and plasma volume depletion by furosemide treatment, 40 mg orally at 6 PM, 12 AM, and 6 AM for
three doses only (13), or three days of very restricted sodium in-

take, 10 to 20 mEq/day. For each, the blood sample is obtained
in the moming with the patient seated, after four hours of walking, standing, and sitting. The three doses of furosemide are
more likely to produce symptoms, dizziness and polyuria, and
are potentially more hazardous for the risk of acute hypotension
than is the three-day period of restricted sodium intake, but the
severity of this sodium restriction will usually require the special
dietary preparation achieved only in a hospital. Plasma renin
activity differs among groups of patients, but a result less than
2.0 ng/mL/hr after either of these two stimulation procedures
demonstrates low plasma renin activity (14), a requisite for the
diagnosis of primary aldosteronism. Plasma renin activity is
lower in patients with aldosterone-producing adenoma than in
those with idiopathic hyperaldosteronism, but the degree of low

Table 2
Establishing the Diagnosis of Primary Aldosteronism
(A) Protocol used in this series to assess aldosterone secretion by measurement of plasma aldosterone after saline
infusion:
1. Discontinue medications at least two weeks before testing. Use methyldopa or guanethidine to treat high
blood pressure if necessary.
2. Treat with potassium chloride, 20 mEq three times daily.
3. Infuse two liters of normal saline intravenously during four hours.
4. Obtain a blood sample at end of the saline infusion for measurement of aldosterone and potassium
concentrations.
Results in patients in this series:

Plasma aldosterone (ng/dL) after
saline infusion
Median
Range

Unilateral
Primary Aldosteronism
(N = 9)

Idiopathic
Hyperaldosteronism
(N = 10)

28
4-82

14
5-21

(B) Protocol used in this series to assess aldosterone secretion by measurement of urinary excretion during
sodium treatment:
1. Discontinue medications at least two weeks before testing. Use methyldopa or guanethidine to treat high
blood pressure if necessary.
2. Treat with potassium chloride, 20 mEq three times daily.
3. Three days before collecting urine, begin sodium chloride treatment, 3 g of supplemental sodium chloride three times daily with meals. (This is 55 mEq sodium TID.)
4. On the third day of sodium treatment, collect urine for 24 hours for measurement of aldosterone, volume,
creatinine, and sodium.
Results in patients in this series:

Urinary aldosterone (jJi.g/24 hr)
during sodium treatment
Median
Range

Unilateral
Primary Aldosteronism
(N = 10)

Idiopathic
Hyperaldosteronism
(N = 12)

37
19-93

20
10-35

Unilateral
Primary Aldosteronism
(N = 13)

Idiopathic
Hyperaldosteronism
(N = 14*)

0.2
not detectable-0.8

0.5
O.I-I.O

(C) Stimulated plasma renin activity:

Plasma renin activity (ng/mL/hr)
after furosemide and upright
posture
Median
Range
*One patient was not tested with this protocol.
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renin activity in the individual patient with primary aldosteronism is not a useful discriminate between the two conditions
[Table 2(C)].

Selecting Patients for Adrenalectomy
Measurements of blood pressure, potassium, aldosterone,
and renin activity determine the diagnosis of primary aldosteronism and can give a clue to the presence of unilateral prijjjary aldosteronism. However, recommending adrenalectomy
as treatment with the intent to cure the disorder requires demonstrating that unilateral adrenal disease is present and identifying
which adrenal is abnormal.
Adrenal cortical scintigraphy during dexamethasone treatment (15) and computed adrenal tomography are the two imaging techniques that have been helpful in identifying an aldosterone-producing adenoma:
Case 7—A 31-year-old woman presented with severe hypertension
(240/130 mm Hg) and hypokalemia (2.0 mEq/L). During sodium administration her aldosterone was very high in the urine (93 ix.g/24 hr)
and plasma (82 ng/dL), and the plasma renin activity was not detectable
after three doses of furosemide and upright posture testing. Computed
adrenal tomography was performed to detect an aldosteronoma, and the
adrenal glands appeared to be nonnal. Adrenal cortical scintigraphy
was performed during dexamethasone treatment, and an early appearing, unilateral image was seen in the area of the left adrenal gland (Fig
2). Left adrenalectomy removed a 2 cm cortical adenoma, which
resulted in normal serum potassium and blood pressure.

Fig 2—The early-appearing (4 days), unilateral left adrenal
image (arrow) in case 7 from adrenal cortical scintigraphy utilizing 131-iodine iodomethyl 19-norcholesterol (NP-59) during
dexamethasone treatment. This is a diagnostic finding of unilateral primary aldosteronism.

Adrenal cortical scintigraphy with 131-iodine iodomethyl 19norcholesterol (NP-59) can be more sensitive and accurate than
computed adrenal tomography in identifying an aldosteroneproducing adenoma. The radiochemical NP-59 is taken up by
steroid-synthesizing tissue as is cholesterol as a precursor for
hormone synthesis. When dexamethasone treatment is given,

Cortisol synthesis is markedly decreased, and an adrenal image
within five days after injection shows the site of the excessive
aldosterone production. The protocol for this test is shown in
Table 3. An aldosterone-producing adenoma leads to low aldosterone secretion in the other adrenal gland, and a unilateral
image would be due to the adenoma. The presence of idiopathic

Table 3
Localizing Unilateral Primary Aldosteronism by Adrenal Cortical
Scintigraphy During Dexamethasone TVeatment
Protocol to detect unilateral primary aldosteronism by adrenal cortical scintigraphy using the isotope NP-59:
1.
2.
3.
4.
5.
6.
7.

Discontinue medications at least two weeks before testing. Use methyldopa or guanethidine to treat
high blood pressure ifnecessary and use potassium treatment.
OneweekbeforeinjectionofNP-59,begintreatmentwithdexamethasone, 1 mg orally four times daily,
and continue it until an adequate scan result has been obtained.
Two days before injection of NP-59, begin treatment with iodine solution, three drops in water twice
daily, and continue this for two weeks.
On the day of injection, before the injection obtain a blood sample for measurement of aldosterone and
potassium.
Intravenous injection of the isotope NP-59.
Obtain the first adrenal scan three days after the injection.
Obtain scans on days four and five, as indicated, to obtain an adequate result.

Results in patients in this series:
Unilateral
Primary Aldosteronism
(N = I I )
Unilateral
No
Image
Image
10
1*

Idiopathic
Hyperaldosteronism
(N = 13)
Bilateral
No
Images
Image
II
2

'Adrenal venous sampling showed unilateral primary aldosteronism, and adrenalectomy confirmed the presence of an
aldosterone-producing adenoma.
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X
Fig 4—The appearance of an aldosterone-producing
adenoma by magnetic resonance imaging (arrow).

Fig 3—The early-appearing (3 days), bilateral adrenal images
(arrows) from adrenal cortical scintigraphy utilizing 131-iodine
iodomethyl 19-norcholesterol (NP-59) during dexamethasone
treatment. This is a diagnostic finding of bilateral primary
aldosteronism.
hyperaldosteronism, a bilateral adrenal disease not curable by
surgery, can also be detected by scintigraphy:
Case 8—A 27-year-old woman presented with asymptomatic hypertension and hypokalemia. Her urinary aldosterone excretion was high
(16 M-g/24 hr) during sodium treatment, and the stimulated plasma renin
activity was low (0.8 ng/mL/hr). Computed adrenal tomography
showed the right adrenal gland to be normal, but the left adrenal could
not be identified. Adrenal cortical scintigraphy during dexamethasone
treatment showed bilateral adrenal images three days after injection of
the isotope (Fig 3), and she was treated medically for idiopathic
hyperaldosteronism.
The accuracy of scintigraphy for detecting an aldosteronoma
has not been rigorously tested because patients with apparently
bilateral adrenal disease have not undergone adrenal surgery
after early attempts (mostly preceding availability of scintigraphy) at surgical treatment of bilateral disease failed to cure the
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adrenal

disorder A unilateral, early image, though, is strong evidence
for unilateral primary aldosteronism which can be treated successfully by surgery. Adrenal scintigraphy is a test of adrenal
function and thereby more useful than computed tomography
which shows adrenal form without information about function.
Nonfunctioning adrenal adenomas are present in high enough
incidence for computed tomography results to be misleading.
Table 3 shows the experience with scintigraphy in patients with
primary aldosteronism at Henry Ford Hospital. Magnetic resonance imaging would be an extraordinarily useful technique i f i t
could demonstrate adrenal enlargement and hyperfunction,
without the necessity of contrast media or a radioisotope. Fig 4
shows a magnetic resonance image of an aldosterone-producing
adenoma.
The direct demonstration of unilateral primary aldosteronism
is more certain by adrenal vein sampling for plasma aldosterone
measurements. This invasive procedure can be used when conflicting results are obtained from attempts to identify an aldosteronoma by other methods:
Case 9—A 40-year-old man presented with moderately severe
hypertension (210/104 mm Hg) and hypokalemia (2.9 mEq/L). Primary
aldosteronism was demonstrated by high aldosterone during sodium
treatment (plasma: 44 ng/dL; urine: 34 fxg/24 hr) and low renin activity
(0.1 ng/mL/hr) after furosemide and upright posture testing. Computed
adrenal tomography suggested an enlargement of the right adrenal, but
adrenal cortical scintigraphy did not show an early image in the area of
either adrenal gland, and his plasma aldosterone increased during upright posture in the moming (as the plasma Cortisol decreased). These
findings were not congment for arightadrenal aldosteronoma, so adrenal vein sampling for aldosterone was perfonned during ACTH inf"'
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Case 10Pertension.
'^gh intake
^^ulation.

sion. The ratio of aldosterone to Cortisol was 23 in the right adrenal
vein, 0.7 in the left adrenal vein, and 2.8 in the vena cava caudad to the
adrenal veins, and right adrenalectomy was recommended and performed. Therightadrenal appeared nonnal as a surgical specimen, but
it contained an 8 mm adenoma, and subsequentiy his potassium and
blood pressure were normal.
The usefulness of the measurement of aldosterone in the adrenal veins is dependent upon the accurate placement of the
catheter in the veins and upon a method of detecting and adjusting for the effect of endogenous ACTH on the secrerion of
aldosterone by both the diseased and normal tissue. The measurement of Cortisol in the adrenal vein samples will aid in
demonstrating the location of the catheter (Adrenal venography
should be minimized because of its risk of adrenal hemorrhage
from the pressure of the contrast media injection.) Comparing the Cortisol concentrations in the two veins can detect differences in ACTH stimulation to the two adrenals at the two
times of sampling. (Simultaneous, bilateral catheterization and
sampling are too hazardous.) An additional method of compensating for differing effects of stress on the aldosterone measurements is to infuse ACTH during the procedure (8). This will
blunt the effect of endogenous ACTH. The ratio of aldosterone
to Cortisol in the samples from the adrenal veins and inferior
vena cava caudad to the adrenal veins during the infusion of
ACTH will more accurately identify unilateral aldosteronism
than the measurement of aldosterone only without infusion. The
ratio is higher in the vein of the affected adrenal, and in the other
adrenal vein it is similar to or lower than that in the inferior vena
cava. The ACTH infusion is 0.25 mg given intravenously during
the one to two hours of the procedure. The infusion should begin
about one hour before sampling to provide near constant, highdegree stimulation of aldosterone secretion.
Another testing procedure can give a strong clue to the presence of an aldosterone-producing adenoma, although it cannot
identify which adrenal contains the adenoma. This test is the
measurement of the response of plasma aldosterone to upright
posture in the moming (16):
Case 3—Adrenal scintigraphy was performed during this woman's
evaluation, but she had discontinued the dexamethasone treatment,
thereby invalidating the results. The response of her plasma aldosterone
to upright posture in the moming was utilized to obtain sufficient rationale for repeating the scintigraphy. After absolutely recumbent posture ovemight her plasma aldosterone was 58 ng/dL; after four hours of
upright posture, walking or standing with sitting 15 minutes of each
hour, from 8 AM until 12 PM, her plasma aldosterone was 25 ng/dL.
Concomitant Cortisol measurements were 17 and 11 p-g/dL, respectively. This was sufficient evidence for the presence of an aldosteroneproducing adenoma to proceed with the second scintigraphy, which
showed an early, unilateral image. Adrenalectomy removed an
aldosteronoma and cured her aldosteronism.

Table 4
Identifying Unilateral Primary Aldosteronism
by Determining the Response of Plasma Aldosterone
Unilateral
Primary Aldosteronism
(N = 9)
Plasma Aldosterone
During Upright Posture
Decrease
Increase
5
4

Idiopathic
Hyperaldosteronism
(N = 5*)
Plasma Aldosterone
During Upright Posture
Decrease
Increase
0
4

*The plasma aldosterone did not change in one patient with idiopathic hyperaldosteron-

upright posture in the moming. Thesefindingswere sufficient to conclude that he did not have surgically treatable aldosteronism, and he was
treated medically.
The experience with this assessment of the plasma aldosterone response to upright posture in the moming in patients
with primary aldosteronism at Hemy Ford Hospital is depicted
in Table 4.
The presence of an aldosterone-producing adenoma is not an
absolute indication to remove it. This disorder is not known to
transform into a malignant lesion or to have a certainly progressive natural history. The hypertension and hypokalemia will
remain active problems in need of treatment, and treatment with
spironolactone has been used in place of adrenalectomy.
Adrenalectomy will cure the hypokalemia, but its effect on
the hypertension is not 100% curative; 60% of patients will be
cured, and 90% will have importantly improved high blood
pressure. To predict which patients are likely to be cured of the
hypertension as well as the hypokalemia, their response to highdose spironolactone can be determined (17):
Case 9—This patient underwent successful surgical treatment for an
aldosterone-producing adenoma. This was predicted by the response of
his blood pressure to treatment with spironolactone, 400 mg daily in
divided doses for three weeks. During this period his blood pressure
decreased from 160/110 to 130/70 mmHg, and his serum potassium increased to 4.9 mEq/L. The retum of his blood pressure to nonnal levels
during high-dose spironolactone treatment predicted its retum to normal levels by adrenalectomy.
Case II—A 34-year-old man was found to have primary aldosteronism with urinary aldosterone excretion of 19 |xg/24 hr during
sodium treatment and a plasma renin activity of 0.8 ng/mL/hr after
furosemide and upright posture testing. He had hypertension and hypokalemia. His blood pressure was 154/102 mm Hg before treatment with
spironolactone and was 154/108 mm Hg after 400 mg of spironolactone
daily for three weeks. Removal of an aldosteronoma cured the hypokalemia but not the hypertension.

TVeatment by Adrenalectomy

When the diagnosis of primary aldosteronism has been established,
and it has been localized to one adrenal gland, adreCase 10—A 40-year-old man presented with hypokalemia and hynalectomy
is an appropriate recommendation, particularly if
pertension. His urinary aldosterone excretion was 34 p,g/24 hr during a
spironolactone
treatment testing predicts that this treatment will
high intake of sodium, and his renin activity was 1.0 ng/mL/hr after
stimulation. Adrenal scintigraphy did not detect images. He underwent cure the hypertension as well as the hypokalemia. To minimize
posture response testing, and his plasma aldosterone increased from 16 therisksof anesthesia and surgery, the hypokalemia and hyperto 44 ng/dL, as his Cortisol decreased from 13 to 7.8 |Jt.g/dL during the tension should be corrected preoperatively:
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Table 5
Response of Blood Pressure to Adrenalectomy in the
12 Patients Who Underwent Adrenalectomy for
Primary Aldosteronism
Normal
Blood Pressure
7

Lower
Blood Pressure
5

No Change in
Blood Pressure
0

Case 4—This older patient with hypertensive heart disease and cerebral vascular disease was at high-risk for surgery. Spironolactone treatment corrected her hypokalemia and hypertension preoperatively, and
adrenalectomy was accomplished without complication.

Case 12—A 43-year-old man with moderately severe hypertension
and primary aldosteronism (urinary aldosterone 58 |i.g/24 hr during sodium treatment) was treated with spironolactone, 200 mg daily, and in
two weeks he passed a urinary stone.
The association between the urinary stone and treatment of
aldosteronism might have been coincidental, but aldosterone
does enhance hydrogen ion excretion, and the development of
hypoaldosteronism, from surgery or from pharmacologic blockade, might have altered the physicochemical state of the urine to
facilitate stone formation in these two patients.

Medical IVeatment of Primary Aldosteronism
Spironolactone blocks the effect of aldosterone on the distal
renal tubules and also affects adrenal synthesis of aldosterone.
The effects of spironolactone on the response of adenoma tissue
to stimuli in vitro were smdied among this group of patients, and
spironolactone was found to influence the response of aldosteronomas to angiotensin II and ACTH (18).
Calcium-channel blocking drags have been used to treat primary aldosteronism, because calcium flux has a role in the stimulation of aldosterone synthesis. This treatment can be utilized
with that of a potassium-retaining drag:

One of the subsets of primary aldosteronism (21) is glucocorticoid-remediable hyperaldosteronism, a familial form of bilateral primary aldosteronism which is suppressed by treatment
with about 1 mg of dexamethasone daily (22). The excessive aldosterone secretion, hypokalemia, and hypertension remit during this treatment. The aldosterone excess remits within a few
days, but the hypertension remits only after about four to six
weeks of treatment:

Case 8—This patient had a family history of hypokalemia and hypertension, but the family members, her father and a brother, were not
available for evaluation. The patient was shown to have bilateral priCase 7—To prepare this patient for adrenalectomy, nifedipine, 40
mg daily, and spironolactone, 100 mg daily, were prescribed. After one mary aldosteronism by adrenal cortical scintigraphy, which utilizes
dexamethasone treatment to suppress Cortisol synthesis. After seven
month of this treatment, her blood pressure had decreased from
days of this dexamethasone treatment her urinary aldosterone was
severely elevated levels to 140/90 mm Hg. Her potassium was normal
9 |Ji.g/24 hr during a sodium intake of greater than 250 mEq daily, an inthen, also.
dication of a persistently excessive secretion of aldosterone not suppressible by glucocorticoid treatment.
The reported experience of treating patients who have an aldosterone-producing adenoma with calcium-channel blocking
An attempt at glucocorticoid suppression has a risk of exacdrags alone, however, suggests that this treatment might not be
erbating
the hypertension in primary aldosteronism, if glucoreliable (19,20).
corticoid-remediable
aldosteronism is not present in the patient.
Adrenalectomy treatment for an aldosteronoma offers a likely
The seven- to 12-day period of dexamethasone treatment as part
cure of the hypertension and hypokalemia and is the usual treatof scintigraphy has been safe, and it might be a suitable test for
ment recommendation. The results of this treatment in this sethe familial disorder by detecting suppression of aldosterone series of patients is shown in Table 5. It is not known how long the
cretion even though the hypertension might not have responded.
blood pressure must be monitored to conclude that the hypertenThe blood pressure should be monitored during the evaluation of
sion has been cured.
patients with or thought to have primary aldosteronism.
Hypoaldosteronism after removal of an aldosterone-producThe medical therapy of primary aldosteronism, not amelioing adenoma can result in hyperkalemia:
rated by dexamethasone treatment, is that of spironolactone,
amiloride, and, recently, calcium-channel blocking drugs.
Case 11—This patient was 34 years old when he presented with
Spironolactone is predictably effective in correcting the hyhypokalemia and refractory hypertension (174/118 mm Hg). Unpokalemia
and is useful in lowering the blood pressure. Amiloprovoked hypokalemia was present (2.7 mEq/L); his urinary aldoride
is
a
potassium-retaining
drug which does not antagonize
sterone was 19 |ig/24 hr, and stimulated plasma renin activity was 0.8
aldosterone or inhibit its synthesis, but it can correct hypokang/mL/hr Adrenal cortical scintigraphy showed a unilateral, rightlemia. An antihypertensive drug is needed with amiloride
sided image, and he underwent removal of aright-sided,aldosteroneproducing adenoma. One week later his urinary aldosterone was 3
treatment and in some patients treated with spironolactone.
|jig/24 hr and his semm potassium was 5.0 mEq/L; four months later his The vasodilators nifedipine and verapamil have been used sucserum potassium was 4.5 mEq/L. His blood pressure was lower (150/98 cessfully for this purpose. It is not certain that they will be
mm Hg) and readily retumed to normal with treatment.
useful alone, but that prospect yet may exist in idiopathic
hyperaldosteronism.
An unexpected result of treatment of primary aldosteronism
The goals of therapy in primary aldosteronism are a normal
in this series was the appearance of a urinary stone:
serum potassium concentration and a normal blood pressure,
Case 11—Two weeks after removal of an aldosterone-producing ad- without adverse effects of therapy. The long-termrisksof unsucenoma, this patient passed a calcium oxalate, urinary stone. Evaluation cessfully treated primary aldosteronism have not been defined,
but they would include those of uncontrolled hypertension. The
to detect the cause of the stone was negative.
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adverse effects of spironolactone primarily are those of its effect
as an antiandrogen with potential for gynecomastia and imporence in men and menstraal irregularities in women.
A more specific therapy of the bilateral form of primary aldosteronism might be possible if its cause were known, but it is
an idiopathic disorder Because the pathology is usually a bilatgral adrenal hyperplasia, it has been suggested that it is a secondary aldosteronism, resulting from a stimulus, such as ACTH
in Cushing's disease. A search for an aldosterone-stimulating
factor has not yet clearly identified such a substance (23,
24). A deficiency of a physiologic inhibitor, such as serotonin
(25) or dopamine (26), has been postulated as a cause of idiopathic hyperaldosteronism, but this does not appear to be the explanation either (27). The role of atrial natriuretic factor, which
niight be a physiologic inhibitor of aldosterone secretion (28),
iias yet to be determined in the pathogenesis of idiopathic
liyperaldosteronism.
Idiopathic hyperaldosteronism is a rare disorder, comprising
about one-half of the patients who have primary aldosteronism,
itself a rare syndrome. Beyond the importance to the person with this unusual endocrine cause of hypertension is the
similarity it has to low-renin essential hypertension, a relatively
common idiopathic type of essential hypertension in which aldosterone secretion is not consistentiy high, but in which there
appears an inappropriate degree of aldosterone secretion (29).
To the extent that the pathophysiology of idiopathic hyperaldosteronism is similar to that of low-renin essential hypertension, the search for the cause of idiopathic hyperaldosteronism
is important.
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